Related Experiment Videos

Use of topiramate in localization-related epilepsy in children

K D Holland1, P E Wyllie

  • 1Department of Neurology, The Cleveland Clinic, OH 44195, USA.

Journal of Child Neurology
|February 24, 2001
PubMed

Insights

Topiramate is a safe and effective treatment for refractory partial epilepsy in children. Higher doses may be required for pediatric patients due to faster clearance, with cognitive issues and weight loss being potential side effects.

Area of Science:

  • Pediatric Neurology
  • Pharmacology
  • Epilepsy Treatment

Background:

  • Refractory partial epilepsy in children presents significant treatment challenges.
  • Evaluating the safety and efficacy of antiepileptic drugs in pediatric populations is crucial.
  • Understanding pharmacokinetic differences between children and adults is essential for optimal drug dosing.

Purpose of the Study:

  • To assess the safety and efficacy of topiramate in pediatric patients with refractory partial epilepsy.
  • To compare the pharmacokinetic profile of topiramate in children versus adults.
  • To identify potential adverse effects and compare them with other anticonvulsant medications.

Main Methods:

  • Review of clinical data on topiramate use in children with refractory partial epilepsy.
  • Analysis of pharmacokinetic studies comparing topiramate clearance in pediatric and adult populations.
  • Comparative assessment of adverse event profiles, including idiosyncratic reactions.

Main Results:

  • Topiramate demonstrates safety and efficacy in treating refractory partial epilepsy in children.
  • Children exhibit greater topiramate clearance than adults, suggesting a need for higher dosages.
  • While generally well-tolerated, cognitive dysfunction, weight loss, and renal stones are potential concerns. Serious idiosyncratic reactions are infrequent compared to other anticonvulsants.

Conclusions:

  • Topiramate is a viable therapeutic option for refractory partial epilepsy in pediatric populations.
  • Dosing adjustments for topiramate in children are necessary due to pharmacokinetic variations.
  • The risk-benefit profile of topiramate in children favors its use, given its favorable safety compared to alternatives for severe epilepsy.

Related Concept Videos